MX363561B - Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. - Google Patents
Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.Info
- Publication number
- MX363561B MX363561B MX2013013388A MX2013013388A MX363561B MX 363561 B MX363561 B MX 363561B MX 2013013388 A MX2013013388 A MX 2013013388A MX 2013013388 A MX2013013388 A MX 2013013388A MX 363561 B MX363561 B MX 363561B
- Authority
- MX
- Mexico
- Prior art keywords
- testosterone
- low
- present
- gels
- sexual
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 26
- 229960003604 testosterone Drugs 0.000 title abstract 13
- 238000013270 controlled release Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000499 gel Substances 0.000 abstract 5
- 230000001568 sexual effect Effects 0.000 abstract 5
- 230000036765 blood level Effects 0.000 abstract 3
- 206010002261 Androgen deficiency Diseases 0.000 abstract 1
- 206010002652 Anorgasmia Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 238000009165 androgen replacement therapy Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000002741 palatine tonsil Anatomy 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 230000001020 rhythmical effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000021595 spermatogenesis Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000000153 supplemental effect Effects 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486324P | 2011-05-15 | 2011-05-15 | |
| US201161486634P | 2011-05-16 | 2011-05-16 | |
| PCT/IB2012/001127 WO2012156822A1 (en) | 2011-05-15 | 2012-05-15 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013388A MX2013013388A (es) | 2014-09-15 |
| MX363561B true MX363561B (es) | 2019-03-27 |
Family
ID=46579248
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013388A MX363561B (es) | 2011-05-15 | 2012-05-15 | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. |
| MX2013013369A MX2013013369A (es) | 2011-05-15 | 2012-05-15 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino. |
| MX2019003340A MX374398B (es) | 2011-05-15 | 2012-05-15 | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. |
| MX2020008599A MX395212B (es) | 2011-05-15 | 2012-05-15 | Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013369A MX2013013369A (es) | 2011-05-15 | 2012-05-15 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino. |
| MX2019003340A MX374398B (es) | 2011-05-15 | 2012-05-15 | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. |
| MX2020008599A MX395212B (es) | 2011-05-15 | 2012-05-15 | Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal. |
Country Status (16)
| Country | Link |
|---|---|
| EP (3) | EP3977982A1 (cg-RX-API-DMAC7.html) |
| JP (9) | JP6152092B2 (cg-RX-API-DMAC7.html) |
| KR (10) | KR20200118228A (cg-RX-API-DMAC7.html) |
| CN (4) | CN110613679A (cg-RX-API-DMAC7.html) |
| AR (2) | AR086409A1 (cg-RX-API-DMAC7.html) |
| AU (11) | AU2012257492A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112013029336B1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2836405C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2714006T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201391701A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2859784T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL229401A0 (cg-RX-API-DMAC7.html) |
| MX (4) | MX363561B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2714006T3 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2012156820A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201309264B (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| KR20200118228A (ko) * | 2011-05-15 | 2020-10-14 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
| US8971800B2 (en) * | 2011-05-31 | 2015-03-03 | Qualcomm Incorporated | Methods and apparatus for improving NFC activation and data exchange reporting mechanisms |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| US20140171918A1 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| EP3054957B1 (en) * | 2013-10-07 | 2019-10-02 | Antares Pharma, Inc. | Hematocrit modulation through needle assisted jet injection of testosterone |
| EP4062918A1 (en) * | 2014-02-19 | 2022-09-28 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
| MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
| WO2016123317A1 (en) * | 2015-01-28 | 2016-08-04 | Prometheon Pharma, Llc | Topical formulations of growth factors |
| US10219894B2 (en) * | 2015-06-29 | 2019-03-05 | 480 Biomedical, Inc. | Implantable scaffolds for treatment of sinusitis |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
| AU2017206048B2 (en) * | 2016-01-07 | 2023-04-13 | Viramal Limited | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| MX2018012967A (es) | 2016-04-25 | 2019-03-06 | Koska Family Ltd | Sistema de suministro medico. |
| WO2017208072A2 (en) * | 2016-06-02 | 2017-12-07 | Acerus Pharmaceutical Corporation | Nasal cannabidiol compositions |
| SG11201810628XA (en) * | 2016-06-03 | 2018-12-28 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| KR20190109452A (ko) | 2017-01-20 | 2019-09-25 | 엠 이티 피 파마 아게 | 대기 오염 물질에의 노출 위험을 감소시키기 위한 비강 약학적 조성물 |
| WO2018231027A1 (ko) * | 2017-06-17 | 2018-12-20 | 엘지전자(주) | 무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치 |
| EP3710086A4 (en) | 2017-11-17 | 2021-11-17 | Koska Family Limited | SYSTEMS AND PROCESSES FOR FLUID DISPENSERS |
| JP7321096B2 (ja) * | 2017-11-27 | 2023-08-04 | あすか製薬株式会社 | 粉末経鼻投与製剤 |
| SG11202007303YA (en) * | 2018-02-02 | 2020-08-28 | Aytu Bioscience Inc | Methods of testosterone therapy |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| CN108771622B (zh) * | 2018-07-11 | 2022-01-07 | 尹振图 | 一种自闭式针形滴嘴及眼药水瓶 |
| CA3117842A1 (en) | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
| ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
| US20200170962A1 (en) | 2018-11-30 | 2020-06-04 | F. Markus Leweke | Nasal cannabidiol compositions |
| PH12021551396A1 (en) * | 2018-12-14 | 2022-05-11 | Acerus Biopharma Inc | Active ester derivatives of testosterone, compositions and uses thereof |
| USD1052082S1 (en) | 2020-06-01 | 2024-11-19 | Koska Family Limited | Sealed fluid container |
| CN112121049B (zh) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用 |
| EP4247332A1 (en) * | 2020-11-19 | 2023-09-27 | Acousia Therapeutics GmbH | Non-aqueous gel composition |
| GB202307501D0 (en) * | 2023-05-19 | 2023-07-05 | Lawley Pharmaceuticals Pty Ltd | Process for preparing dispensable testosterone cream |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| DE4214953C2 (de) | 1992-05-06 | 1995-05-18 | Arrowdean Ltd | Arzneimittel zur Erhöhung des Testosteronspiegels |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5576071A (en) | 1994-11-08 | 1996-11-19 | Micron Technology, Inc. | Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds |
| JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
| EP1510213B1 (en) * | 1997-11-10 | 2008-12-31 | Strakan International Limited | Penetration enhancing and irritation reducing systems comprising testosterone |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| WO2005039531A1 (en) * | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| EP1450739A4 (en) * | 2001-10-12 | 2008-12-17 | Cns Inc | NASAL MOISTURIZING GEL AND APPLICATOR |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| DK1530965T3 (da) * | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
| NZ555641A (en) * | 2004-12-09 | 2010-10-29 | Bayer Animal Health Gmbh | Stabilisation of glucocorticoid esters with acids |
| EA019214B1 (ru) * | 2005-06-03 | 2014-02-28 | АКРУКС ДиДиЭс ПиТиУай ЭлТиДи | Способ лечения или профилактики заболеваний, вызванных дефицитом андрогенов у взрослых мужчин |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| CN101099742A (zh) * | 2006-07-06 | 2008-01-09 | 上海富海科申药业有限公司 | 能够减少皮肤刺激的睾酮凝胶制剂 |
| PT2068825E (pt) * | 2006-10-04 | 2011-02-11 | M & P Patent Ag | Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores |
| CN101754764A (zh) * | 2007-03-23 | 2010-06-23 | 优尼麦德药物股份有限公司 | 治疗小儿性腺机能减退的组合物和方法 |
| WO2009037813A1 (ja) * | 2007-09-20 | 2009-03-26 | Shiseido Company, Ltd. | 経皮吸収製剤 |
| ES2628507T3 (es) * | 2007-11-13 | 2017-08-03 | Athenion Ag | Esteroides C-19 para el tratamiento de la celulitis |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| KR20200118228A (ko) * | 2011-05-15 | 2020-10-14 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
-
2012
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko not_active Ceased
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/en not_active Withdrawn
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Ceased
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 KR KR1020247037387A patent/KR20240162608A/ko active Pending
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Ceased
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/en not_active Ceased
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active Active
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/en active Active
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/en active Active
- 2012-05-15 MX MX2019003340A patent/MX374398B/es active IP Right Grant
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 CA CA2836405A patent/CA2836405C/en active Active
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active Active
- 2012-05-15 CA CA2836398A patent/CA2836398C/en active Active
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Ceased
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Ceased
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko not_active Ceased
- 2012-05-15 MX MX2020008599A patent/MX395212B/es unknown
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 PL PL12748245T patent/PL2714006T3/pl unknown
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko not_active Ceased
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh active Active
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 CA CA3034552A patent/CA3034552C/en active Active
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/en not_active Ceased
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
-
2013
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
-
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
-
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
-
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
-
2024
- 2024-08-23 AU AU2024216312A patent/AU2024216312A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363561B (es) | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. | |
| MX2016005574A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
| MX2019012197A (es) | Tratamiento de trastornos del ritmo circadiano. | |
| CO6450651A2 (es) | Terapia complementaria contra el cancer | |
| MX2020012689A (es) | Tratamiento de trastornos del ritmo circadiano. | |
| MX2017012982A (es) | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| BR112017023170A2 (pt) | dispositivo de banho medicinal e seu uso | |
| CY1124812T1 (el) | Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου | |
| BR112015028613A2 (pt) | análogos de uréia com ligações por pontes substituída como moduladores de sirtuína | |
| MX2015005038A (es) | Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. | |
| MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| BR112016002580A2 (pt) | composição para tratamento antienvelhecimento de pele | |
| EA201690571A1 (ru) | Улучшенное портативное массажное устройство расслабляющей терапии для головы | |
| CO2025009577A2 (es) | Formulaciones líquidas de melatonina | |
| AR098314A1 (es) | Superagonistas de acción prolongada de hormonas glicoproteicas | |
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
| UA113183C2 (xx) | Спосіб лікування адикції | |
| MX2021004656A (es) | Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa. | |
| HK1196261A (en) | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration | |
| EA201600229A1 (ru) | Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита | |
| RU2013154077A (ru) | Способ биологической стрессовой психотерапии (биостресспсихотерапии) | |
| TWD180808S (zh) | 美容用按摩器 |